Pub Date : 2025-03-06DOI: 10.1016/j.genhosppsych.2025.03.003
Ziyi Wang , Kaixin Zhang , Chongke Zhong , Zhengbao Zhu , Xiaowei Zheng , Pinni Yang , Bizhong Che , Yaling Lu , Yonghong Zhang , Tian Xu
Objective
Our study aimed at evaluating the association between plasma human cartilage glycoprotein-39 (YKL-40) and depressive symptoms at 3 months among acute ischemic stroke patients.
Methods
Plasma YKL-40 levels were measured in 619 patients with ischemic stroke who participated in the China Antihypertensive Trial in Acute Ischemic Stroke (CATIS). The patients' depressive symptoms at 3 months after stroke were assessed using the Hamilton Rating Scale for Depression (HRSD-24).
Results
During the 3-month follow-up period, 242 (39.1 %) participants were classified as experiencing depressive symptoms. Patients in the highest quartile of YKL-40 had a 1.98-fold (95 %CI: 1.19–3.30, P for trend = 0.02) risk of depressive symptoms compared with those in the lowest quartile. Per 1-SD increase of logarithm-transformed YKL-40 was associated with a 32 % (95 % CI: 10 %–58 %) increased risk for the depressive symptoms. The multiple-adjusted spline regression model confirmed dose-response relationships between YKL-40 levels and depressive symptoms (P for linearity = 0.02). Adding YKL-40 to a model containing conventional risk factors significantly improved the discriminatory power (area under the receiver operating characteristic curve improved by 0.02, P = 0.04) and reclassification power for depressive symptoms (net reclassification improvement = 18.77 %, P = 0.02; integrated discrimination improvement = 1.30 %, P = 0.005).
Conclusions
Elevated YKL-40 levels might be a potential risk marker of depressive symptoms at 3 months among acute ischemic stroke patients.
{"title":"Plasma human cartilage glycoprotein-39 and depressive symptoms among acute ischemic stroke patients","authors":"Ziyi Wang , Kaixin Zhang , Chongke Zhong , Zhengbao Zhu , Xiaowei Zheng , Pinni Yang , Bizhong Che , Yaling Lu , Yonghong Zhang , Tian Xu","doi":"10.1016/j.genhosppsych.2025.03.003","DOIUrl":"10.1016/j.genhosppsych.2025.03.003","url":null,"abstract":"<div><h3>Objective</h3><div>Our study aimed at evaluating the association between plasma human cartilage glycoprotein-39 (YKL-40) and depressive symptoms at 3 months among acute ischemic stroke patients.</div></div><div><h3>Methods</h3><div>Plasma YKL-40 levels were measured in 619 patients with ischemic stroke who participated in the China Antihypertensive Trial in Acute Ischemic Stroke (CATIS). The patients' depressive symptoms at 3 months after stroke were assessed using the Hamilton Rating Scale for Depression (HRSD-24).</div></div><div><h3>Results</h3><div>During the 3-month follow-up period, 242 (39.1 %) participants were classified as experiencing depressive symptoms. Patients in the highest quartile of YKL-40 had a 1.98-fold (95 %CI: 1.19–3.30, <em>P</em> for trend = 0.02) risk of depressive symptoms compared with those in the lowest quartile. Per 1-SD increase of logarithm-transformed YKL-40 was associated with a 32 % (95 % CI: 10 %–58 %) increased risk for the depressive symptoms. The multiple-adjusted spline regression model confirmed dose-response relationships between YKL-40 levels and depressive symptoms (<em>P</em> for linearity = 0.02). Adding YKL-40 to a model containing conventional risk factors significantly improved the discriminatory power (area under the receiver operating characteristic curve improved by 0.02, <em>P</em> = 0.04) and reclassification power for depressive symptoms (net reclassification improvement = 18.77 %, <em>P</em> = 0.02; integrated discrimination improvement = 1.30 %, <em>P</em> = 0.005).</div></div><div><h3>Conclusions</h3><div>Elevated YKL-40 levels might be a potential risk marker of depressive symptoms at 3 months among acute ischemic stroke patients.</div><div><strong>Registration:</strong> URL: <span><span>https://www.clinicaltrials.gov</span><svg><path></path></svg></span>; Unique identifier: <span><span>NCT01840072</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"94 ","pages":"Pages 120-125"},"PeriodicalIF":4.1,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143580254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-06DOI: 10.1016/j.genhosppsych.2025.02.023
Rebecca Philipp , Charlotte Walbaum , Uwe Koch , Karin Oechsle , Thies Daniels , Friederike Helmich , Marlitt Horn , Johanna Junghans , David Kissane , Guntram Lock , Christopher Lo , Anne Mruk-Kahl , Volkmar Müller , Martin Reck , Georgia Schilling , Kornelius Schulze , Johann von Felden , Carsten Bokemeyer , Martin Härter , Sigrun Vehling
Objective
Clinically significant existential distress may impair quality of life and communication about illness. We investigated the presence of existential distress in the form of demoralization, death anxiety, and dignity-related distress, and its co-occurrence with mental disorders in patients with advanced cancer.
Methods
We conducted structured clinical interviews and administered self-report questionnaires to assess existential distress and mental disorders. We recruited patients with different Union for International Cancer Control (UICC) stage IV solid tumors from in- and outpatient oncology and palliative care settings.
Results
A total of 671 patients completed assessments (55 % participation rate, 48 % female, primary tumor site: 28 % lung, 14 % prostate, 11 % breast). Clinically relevant levels of existential distress were present in 46.4 % (95 % CI, 41.7 % to 51.1 %), including demoralization, 12.5 % (95 % CI, 9.6 % to 15.9 %), death anxiety, 27.3 % (95 % CI, 23.2 % to 31.6 %), and dignity-related distress, 38.7 % (95 % CI, 34.2 % to 43.3 %). Frequent existential distress symptoms were sense of entrapment and fear of own and close others' suffering. Mental disorders occurred in 26.2 % (95 % CI, 22.2 % to 30.4 %), including major depression, 8.6 % (95 % CI, 6.2 % to 11.5 %), anxiety disorders, 8.4 % (95 % CI, 6.0 % to 11.3 %), and ICD-11-adjustment disorder, 10.5 % (95 % CI, 7.9 % to 13.7 %). Existential distress and mental disorders co-occurred in 20.0 % (95 % CI, 16.4 % to 24.0 %).
Conclusion
Existential distress is a common, clinically significant problem in patients with advanced cancer. Its recognition in multiprofessional clinical settings can contribute to improve quality of life. Most patients with a mental disorder show comorbid existential distress requiring treatment of both.
{"title":"Existential distress in advanced cancer: A cohort study","authors":"Rebecca Philipp , Charlotte Walbaum , Uwe Koch , Karin Oechsle , Thies Daniels , Friederike Helmich , Marlitt Horn , Johanna Junghans , David Kissane , Guntram Lock , Christopher Lo , Anne Mruk-Kahl , Volkmar Müller , Martin Reck , Georgia Schilling , Kornelius Schulze , Johann von Felden , Carsten Bokemeyer , Martin Härter , Sigrun Vehling","doi":"10.1016/j.genhosppsych.2025.02.023","DOIUrl":"10.1016/j.genhosppsych.2025.02.023","url":null,"abstract":"<div><h3>Objective</h3><div>Clinically significant existential distress may impair quality of life and communication about illness. We investigated the presence of existential distress in the form of demoralization, death anxiety, and dignity-related distress, and its co-occurrence with mental disorders in patients with advanced cancer.</div></div><div><h3>Methods</h3><div>We conducted structured clinical interviews and administered self-report questionnaires to assess existential distress and mental disorders. We recruited patients with different Union for International Cancer Control (UICC) stage IV solid tumors from in- and outpatient oncology and palliative care settings.</div></div><div><h3>Results</h3><div>A total of 671 patients completed assessments (55 % participation rate, 48 % female, primary tumor site: 28 % lung, 14 % prostate, 11 % breast). Clinically relevant levels of existential distress were present in 46.4 % (95 % CI, 41.7 % to 51.1 %), including demoralization, 12.5 % (95 % CI, 9.6 % to 15.9 %), death anxiety, 27.3 % (95 % CI, 23.2 % to 31.6 %), and dignity-related distress, 38.7 % (95 % CI, 34.2 % to 43.3 %). Frequent existential distress symptoms were sense of entrapment and fear of own and close others' suffering. Mental disorders occurred in 26.2 % (95 % CI, 22.2 % to 30.4 %), including major depression, 8.6 % (95 % CI, 6.2 % to 11.5 %), anxiety disorders, 8.4 % (95 % CI, 6.0 % to 11.3 %), and ICD-11-adjustment disorder, 10.5 % (95 % CI, 7.9 % to 13.7 %). Existential distress and mental disorders co-occurred in 20.0 % (95 % CI, 16.4 % to 24.0 %).</div></div><div><h3>Conclusion</h3><div>Existential distress is a common, clinically significant problem in patients with advanced cancer. Its recognition in multiprofessional clinical settings can contribute to improve quality of life. Most patients with a mental disorder show comorbid existential distress requiring treatment of both.</div></div>","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"94 ","pages":"Pages 184-191"},"PeriodicalIF":4.1,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143644306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-06DOI: 10.1016/j.genhosppsych.2025.02.022
Shizhen Wang , Wangjie Xia , Jian Zhang , Mengru Wu , Li Tian
Objective
This meta-analysis aimed to evaluate the effectiveness of internet-based mindfulness interventions on anxiety and depression symptoms in patients with cancer.
Methods
Eight databases (Cochrane Library, PubMed, Embase, and PsycINFO CNKI, Wanfang, VIP, and CBM) were systematically searched from the inception of databases to August 2023 for randomized controlled trials (RCTs). Two independent reviewers rigorously assessed the risk of bias and extracted data using a pre-established form. The meta-analysis, conducted using Stata version 16, calculated pooled effect sizes and 95% confidence intervals (CIs). Sensitivity analysis was employed to find the source of heterogeneity, and potential publication bias was evaluated through funnel plot analysis and the Egger test.
Results
This study included 10 studies, involving a total of 1314 patients. The results of the meta-analysis showed that Internet-based mindfulness interventions were effective in reducing anxiety [SMD = −0.38, 95% CI (−0.51, −0.25), P < 0.01] and depression [SMD = −0.36, 95% CI (−0.49, −0.23), P < 0.01], particularly when the duration of the program was within 8 weeks and each session lasted <45 min. Interventions guided by therapists proved to be more effective than those without therapist guidance in improving anxiety and depression in cancer patients, and synchronous online interaction with therapists were found to yield the most noticeable improvements in anxiety and depression.
Conclusion
Internet-based mindfulness interventions, especially synchronous online interaction with therapists, contribute to alleviating anxiety and depression symptoms in cancer patients. The effectiveness is more pronounced when the intervention duration per session is limited to 45 min and the overall intervention duration is within 8 weeks. The medium to long-term efficacy of the intervention needs further validation through more high-quality research.
{"title":"Effects of internet-based mindfulness interventions on anxiety and depression symptoms in cancer patients: A meta-analysis","authors":"Shizhen Wang , Wangjie Xia , Jian Zhang , Mengru Wu , Li Tian","doi":"10.1016/j.genhosppsych.2025.02.022","DOIUrl":"10.1016/j.genhosppsych.2025.02.022","url":null,"abstract":"<div><h3>Objective</h3><div>This meta-analysis aimed to evaluate the effectiveness of internet-based mindfulness interventions on anxiety and depression symptoms in patients with cancer.</div></div><div><h3>Methods</h3><div>Eight databases (Cochrane Library, PubMed, Embase, and PsycINFO CNKI, Wanfang, VIP, and CBM) were systematically searched from the inception of databases to August 2023 for randomized controlled trials (RCTs). Two independent reviewers rigorously assessed the risk of bias and extracted data using a pre-established form. The meta-analysis, conducted using Stata version 16, calculated pooled effect sizes and 95% confidence intervals (CIs). Sensitivity analysis was employed to find the source of heterogeneity, and potential publication bias was evaluated through funnel plot analysis and the Egger test.</div></div><div><h3>Results</h3><div>This study included 10 studies, involving a total of 1314 patients. The results of the meta-analysis showed that Internet-based mindfulness interventions were effective in reducing anxiety [SMD = −0.38, 95% CI (−0.51, −0.25), <em>P</em> < 0.01] and depression [SMD = −0.36, 95% CI (−0.49, −0.23), P < 0.01], particularly when the duration of the program was within 8 weeks and each session lasted <45 min. Interventions guided by therapists proved to be more effective than those without therapist guidance in improving anxiety and depression in cancer patients, and synchronous online interaction with therapists were found to yield the most noticeable improvements in anxiety and depression.</div></div><div><h3>Conclusion</h3><div>Internet-based mindfulness interventions, especially synchronous online interaction with therapists, contribute to alleviating anxiety and depression symptoms in cancer patients. The effectiveness is more pronounced when the intervention duration per session is limited to 45 min and the overall intervention duration is within 8 weeks. The medium to long-term efficacy of the intervention needs further validation through more high-quality research.</div></div>","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"94 ","pages":"Pages 126-141"},"PeriodicalIF":4.1,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143591692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-04DOI: 10.1016/j.genhosppsych.2025.03.001
Monica Widyaswari , Rikardus Feribertus Nikat , Dyah Permata Sari
{"title":"The digital mental health revolution: How AI and big data are transforming modern therapy","authors":"Monica Widyaswari , Rikardus Feribertus Nikat , Dyah Permata Sari","doi":"10.1016/j.genhosppsych.2025.03.001","DOIUrl":"10.1016/j.genhosppsych.2025.03.001","url":null,"abstract":"","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"94 ","pages":"Pages 118-119"},"PeriodicalIF":4.1,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143580255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-02DOI: 10.1016/j.genhosppsych.2025.02.026
Kevin Skoblenick , Ryan Yip , Atul Khullar , Roger S. McIntyre , Jennifer Swainson
{"title":"Letter to the editor in response to: Blood pressure changes during ketamine infusion for the treatment of depression","authors":"Kevin Skoblenick , Ryan Yip , Atul Khullar , Roger S. McIntyre , Jennifer Swainson","doi":"10.1016/j.genhosppsych.2025.02.026","DOIUrl":"10.1016/j.genhosppsych.2025.02.026","url":null,"abstract":"","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"94 ","pages":"Pages 110-111"},"PeriodicalIF":4.1,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-02DOI: 10.1016/j.genhosppsych.2025.02.027
Monica Widyaswari , Ali Fakhrudin
{"title":"Harnessing AI and mindfulness: A new wave of digital mental health solutions","authors":"Monica Widyaswari , Ali Fakhrudin","doi":"10.1016/j.genhosppsych.2025.02.027","DOIUrl":"10.1016/j.genhosppsych.2025.02.027","url":null,"abstract":"","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"94 ","pages":"Pages 108-109"},"PeriodicalIF":4.1,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-02DOI: 10.1016/j.genhosppsych.2025.02.025
Hui-Min Hsieh , Yu-Hsin Wang , Hsueh-Fen Chen
Objective
Few population-based studies with large sample sizes have examined the long-term effects of integrated diabetes care in patients with schizophrenia. This study aimed to examine the association between participation in the nationwide diabetes Pay-for-Performance (DM-P4P) program and both health outcomes and healthcare utilization in individuals with schizophrenia comorbid with type 2 diabetes in Taiwan.
Study setting and design
This was a longitudinal, real-world, nested case-control follow-up study from 2015 to 2021 in Taiwan.
Data source and analytical sample
Multiple national population-based databases were used, including Taiwanese population-based longitudinal National Health Insurance (NHI) claims database, registry for NHI enrollment, catastrophic illness registry, board-certificated specialist registry, and registry for health care facilities. A total of 6172 schizophrenia patients with type 2 diabetes and matched controls were compared on a set of process outcome, health utilization, and direct medical cost measures between DM-P4P and non-P4P patients, with a follow-up period of at least three years. Generalized linear regression models were used to investigate the factors influencing participation in the DM-P4P program and to compare health outcomes.
Principle findings
Schizophrenia patients with more severe diabetes complications and chronic comorbid conditions, or those who had previously participated in a schizophrenia P4P program, were more likely to participate in the program. Those who participated in the DM-P4P program were more likely to receive regular diabetes check-ups, and to have had more DM-related outpatient visits but fewer emergency room visits, hospitalizations, and related expenditures, as well as lower all-cause mortality, than non-DM-P4P patients.
Conclusions
The nationwide DM-P4P program positively affected health outcomes and healthcare utilization among people with schizophrenia comorbid with type 2 diabetes. Policymakers should consider establishing incentive mechanisms to encourage integrated care for schizophrenia patients with diabetes.
{"title":"Associations between participation in a diabetes pay-for-performance program and health outcomes and healthcare utilization among people with comorbid schizophrenia and type 2 diabetes in Taiwan","authors":"Hui-Min Hsieh , Yu-Hsin Wang , Hsueh-Fen Chen","doi":"10.1016/j.genhosppsych.2025.02.025","DOIUrl":"10.1016/j.genhosppsych.2025.02.025","url":null,"abstract":"<div><h3>Objective</h3><div>Few population-based studies with large sample sizes have examined the long-term effects of integrated diabetes care in patients with schizophrenia. This study aimed to examine the association between participation in the nationwide diabetes Pay-for-Performance (DM-P4P) program and both health outcomes and healthcare utilization in individuals with schizophrenia comorbid with type 2 diabetes in Taiwan.</div></div><div><h3>Study setting and design</h3><div>This was a longitudinal, real-world, nested case-control follow-up study from 2015 to 2021 in Taiwan.</div></div><div><h3>Data source and analytical sample</h3><div>Multiple national population-based databases were used, including Taiwanese population-based longitudinal National Health Insurance (NHI) claims database, registry for NHI enrollment, catastrophic illness registry, board-certificated specialist registry, and registry for health care facilities. A total of 6172 schizophrenia patients with type 2 diabetes and matched controls were compared on a set of process outcome, health utilization, and direct medical cost measures between DM-P4P and non-P4P patients, with a follow-up period of at least three years. Generalized linear regression models were used to investigate the factors influencing participation in the DM-P4P program and to compare health outcomes.</div></div><div><h3>Principle findings</h3><div>Schizophrenia patients with more severe diabetes complications and chronic comorbid conditions, or those who had previously participated in a schizophrenia P4P program, were more likely to participate in the program. Those who participated in the DM-P4P program were more likely to receive regular diabetes check-ups, and to have had more DM-related outpatient visits but fewer emergency room visits, hospitalizations, and related expenditures, as well as lower all-cause mortality, than non-DM-P4P patients.</div></div><div><h3>Conclusions</h3><div>The nationwide DM-P4P program positively affected health outcomes and healthcare utilization among people with schizophrenia comorbid with type 2 diabetes. Policymakers should consider establishing incentive mechanisms to encourage integrated care for schizophrenia patients with diabetes.</div></div>","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"94 ","pages":"Pages 99-107"},"PeriodicalIF":4.1,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1016/j.genhosppsych.2025.02.021
Monica Widyaswari , Ali Fakhrudin , Shobri Firman Susanto
{"title":"Sustaining evidence-based practices in mental health: The role of the EPIS framework","authors":"Monica Widyaswari , Ali Fakhrudin , Shobri Firman Susanto","doi":"10.1016/j.genhosppsych.2025.02.021","DOIUrl":"10.1016/j.genhosppsych.2025.02.021","url":null,"abstract":"","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"94 ","pages":"Pages 97-98"},"PeriodicalIF":4.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143534185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The increasing prevalence of psychological issues among older adults is a significant public health concern. Immersive Virtual Reality (IVR) is being investigated and tested as a potential intervention tool for addressing these issues.
Objective
This review aims to assess the effectiveness of IVR devices in enhancing the psychological well-being of older adults.
Methods
A comprehensive literature search was conducted across the PubMed, EMBASE, Web of Science, and Cochrane Library databases up to January 24, 2024. The Cochrane Risk of Bias Tool for Randomized Trials, version 2, was used to assess the methodological quality of the studies and determine the levels of evidence for the outcomes. Results are reported as Standardized Mean Differences (SMDs) with 95 % Confidence Intervals (CIs).
Results
The primary outcomes of this review were depression and anxiety, with psychological well-being as the secondary outcome. Among the 15 randomized controlled trials (RCTs) included (n = 15), for overall methodological quality, 1 study showed high risk, 6 studies showed some concerns and 8 studies showed low risk. A total of 802 older adults participated across the studies. Compared with control groups, IVR intervention was more effective in reducing depression (SMD -0.608, 95 % CI -0.900 ∼ −0.315, P < 0.001), anxiety (SMD -0.708, 95 % CI -1.119 ∼ −0.297, P = 0.001), and more effective in improving psychological well-being (SMD 0.641, 95 % CI 0.068–1.214, P = 0.028).
Conclusions
IVR has the potential to improve the psychological health of older adults and may be widely applicable in promoting successful aging.
{"title":"The effectiveness of immersive virtual reality on the psychology of older adults: A systematic review and Meta-analysis of randomized controlled trials","authors":"Zhilan Ke , Meng Wei , Fen Yang , Yufei Qiu , Xinhong Zhu , Xiaolian Gao , Jing Zhou , Guiyuan Qiao","doi":"10.1016/j.genhosppsych.2025.02.024","DOIUrl":"10.1016/j.genhosppsych.2025.02.024","url":null,"abstract":"<div><h3>Background</h3><div>The increasing prevalence of psychological issues among older adults is a significant public health concern. Immersive Virtual Reality (IVR) is being investigated and tested as a potential intervention tool for addressing these issues.</div></div><div><h3>Objective</h3><div>This review aims to assess the effectiveness of IVR devices in enhancing the psychological well-being of older adults.</div></div><div><h3>Methods</h3><div>A comprehensive literature search was conducted across the PubMed, EMBASE, Web of Science, and Cochrane Library databases up to January 24, 2024. The Cochrane Risk of Bias Tool for Randomized Trials, version 2, was used to assess the methodological quality of the studies and determine the levels of evidence for the outcomes. Results are reported as Standardized Mean Differences (SMDs) with 95 % Confidence Intervals (CIs).</div></div><div><h3>Results</h3><div>The primary outcomes of this review were depression and anxiety, with psychological well-being as the secondary outcome. Among the 15 randomized controlled trials (RCTs) included (<em>n</em> = 15), for overall methodological quality, 1 study showed high risk, 6 studies showed some concerns and 8 studies showed low risk. A total of 802 older adults participated across the studies. Compared with control groups, IVR intervention was more effective in reducing depression (SMD -0.608, 95 % CI -0.900 ∼ −0.315, <em>P</em> < 0.001), anxiety (SMD -0.708, 95 % CI -1.119 ∼ −0.297, <em>P</em> = 0.001), and more effective in improving psychological well-being (SMD 0.641, 95 % CI 0.068–1.214, <em>P</em> = 0.028).</div></div><div><h3>Conclusions</h3><div>IVR has the potential to improve the psychological health of older adults and may be widely applicable in promoting successful aging.</div></div>","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"94 ","pages":"Pages 86-96"},"PeriodicalIF":4.1,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143534184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-26DOI: 10.1016/j.genhosppsych.2025.02.017
Ye Wang , Zheng Zeng , Changqun Huang , Jing Ma , Jialu Ye , Jiafeng Li , Xiuliang Deng , Lan Zhang
Objectives
The Kessler Psychological Distress Scale (K10) is a 10-item questionnaire designed to measure psychological distress. The present study aimed to validate the factor structure of the K10 and its reliability and validity using a large sample from healthcare professionals in China mainland.
Methods
K10 data were collected in September 19 to October 20, 2023 via anonymous online survey (total sample, N = 8602).
The internal consistency reliability of the K10 was examined. Exploratory factor analysis (N = 4301) and confirmatory factor analysis(N = 4301) were conducted to validate the structural validity.
Results
Exploratory factor analysis revealed two factors, depression (DEP) and anxiety (ANX), which together accounted for 75.91 % of the total variance. Confirmatory factor analysis further supported the two-factor oblique model as the best fit, outperforming the one-factor model. The internal consistency of the K10 was α = 0.952, while the internal consistency coefficients for ANX and DEP were 0.883 and 0.940, respectively.
Conclusions
K10 is a validated and concise tool that serves a dual purpose of screening psychological distress and assessing depressive and anxiety symptoms among healthcare professionals in China.
{"title":"Large-scale validation of the Kessler-10 Scale's psychometric properties among healthcare professionals in China","authors":"Ye Wang , Zheng Zeng , Changqun Huang , Jing Ma , Jialu Ye , Jiafeng Li , Xiuliang Deng , Lan Zhang","doi":"10.1016/j.genhosppsych.2025.02.017","DOIUrl":"10.1016/j.genhosppsych.2025.02.017","url":null,"abstract":"<div><h3>Objectives</h3><div>The Kessler Psychological Distress Scale (K10) is a 10-item questionnaire designed to measure psychological distress. The present study aimed to validate the factor structure of the K10 and its reliability and validity using a large sample from healthcare professionals in China mainland.</div></div><div><h3>Methods</h3><div>K10 data were collected in September 19 to October 20, 2023 via anonymous online survey (total sample, <em>N</em> = 8602).</div><div>The internal consistency reliability of the K10 was examined. Exploratory factor analysis (<em>N</em> = 4301) and confirmatory factor analysis(N = 4301) were conducted to validate the structural validity.</div></div><div><h3>Results</h3><div>Exploratory factor analysis revealed two factors, depression (DEP) and anxiety (ANX), which together accounted for 75.91 % of the total variance. Confirmatory factor analysis further supported the two-factor oblique model as the best fit, outperforming the one-factor model. The internal consistency of the K10 was α = 0.952, while the internal consistency coefficients for ANX and DEP were 0.883 and 0.940, respectively.</div></div><div><h3>Conclusions</h3><div>K10 is a validated and concise tool that serves a dual purpose of screening psychological distress and assessing depressive and anxiety symptoms among healthcare professionals in China.</div></div>","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"94 ","pages":"Pages 112-117"},"PeriodicalIF":4.1,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号